Analyst deems Novo Nordisk once-weekly insulin has blockbuster potential

Even so, the analyst from Danish bank Sydbank doesn’t think insulin icodec will reach the same level as the pharmaceutical giant’s popular GLP-1 drugs.

by marketwire, translated by daniel pedersen

Novo Nordisk’s experimental new type 2 diabetes insulin icodec has the potential to reach blockbuster heights, which is achieved once a drug generates more than USD 1bn within a financial year, assesses Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Novo Nordisk nails another phase III study of once-weekly insulin
For subscribers
Novo Nordisk expects phase III data for diabetes app imminently
For subscribers
Novo Nordisk hopes to begin approval process of once-weekly insulin in H1 2023
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

EU Health Commissioner Stella Kyriakides has received an open letter from trade association Medtech Europe and 34 national organizations. | Photo: Julien Warnand/AP/Ritzau Scanpix

Other

European trade association calls for comprehensive reform of MDR and IVDR

Medtech Europe considers EU regulations to be unpredictable, complex and slow.

For subscribers

Pharma & biotech

Kåre Schultz: Former chairman of Novo Nordisk Foundation cost me the job as Novo Nordisk CEO

For subscribers

Søren Nielsen, CEO of hearing aid company Demant. | Photo: Demant / Pr

Hearing health

Jyske Bank questions Demant's continued momentum

For subscribers

Foto: Jim Vondruska/Reuters/Ritzau Scanpix

Pharma & biotech

Third time's the charm: Novo Nordisk makes new bid to get obesity drug reimbursed in Danish home market

For subscribers

Novo Nordisk Foundation's investment company, Novo Holdings, together with Gurnet Point Capital, has completed the acquisition of the US biotech company Paratek for USD 462 million including debt corresponding to DKK 3.2 billion. | Foto: Novo Holdings / Pr

Pharma & biotech

Novo Holdings completes acquisition of US antibiotics company for DKK 3.2bn

For subscribers

Pharma & biotech

Leo acquisition negotiated with four suitors while struggling to survive

For subscribers

Jefferies on Novo Nordisk: Little risk of semaglutide patent dispute - but could raise concerns
The actual risk of competition from generic drugs is limited, according to Jefferies analyst, although pharmaceutical company Viatris is challenging patents related to Novo Nordisk’s semaglutide.
For subscribers
Media: Issues at Novo Nordisk factory have been known for more than a year
Already in May of last year, the FDA released a report documenting quality control failures at Novo Nordisk’s factory in Clayton, USA, Reuters reports. (Updated)
For subscribers
Novo Nordisk and UNICEF extend joint initiative to combat childhood obesity
As part of the extended agreement, Novo Nordisk will invest USD 8m over the next three years.
For subscribers
Board member appointed as new CEO of Orphazyme
The biotech company prepares new activities.
For subscribers
Eli Lilly sues clinics for selling fake diabetes drug
Novo Nordisk was also out in force in June.
For subscribers
Media: This is why the FDA has reprimanded Novo Nordisk following US plant inspection
Inadequate oversight of batch deviations and messy microbial controls are the cause of an FDA Form 483 for a Novo Nordisk plant in the US, reports media outlet Fierce Pharma.
For subscribers

Novo Nordisk products subject to new US price negotiations

Two Novo Nordisk products are among the ten drugs in the US for which Medicare must renegotiate prices according to new legislation.

For subscribers

Foto: George Frey/Reuters/Ritzau Scanpix

Pharma & biotech

Diabetes patients in UK to get Eli Lilly drug, rivaling Ozempic

Both Novo Nordisk and Lilly have struggled to keep up with demand for the drugs, which are in shortage.

For subscribers

Foto: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Pharma & biotech

Novo Nordisk and UNICEF extend joint initiative to combat childhood obesity

As part of the extended agreement, Novo Nordisk will invest USD 8m over the next three years.

For subscribers

Pharma & biotech

Media: Issues at Novo Nordisk factory have been known for more than a year

Already in May of last year, the FDA released a report documenting quality control failures at Novo Nordisk’s factory in Clayton, USA, Reuters reports. (Updated)

For subscribers

The hearing group WS Audiology, the result of the 2019 merger between Widex and Sivantos, has no plans to integrate the two hearing aid platforms from each of the respective companies before the merger. | Foto: Ws Audiology / Pr

Hearing health

WS Audiology has no plans of merging product platforms

Hearing health group WS Audiology continues to see benefits in having a product platform under both Signia and Widex brands. Analysts also see benefits.

For subscribers